Wall Street analysts expect that Cambrex Co. (NYSE:CBM) will announce $1.10 earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Cambrex’s earnings. The highest EPS estimate is $1.11 and the lowest is $1.09. Cambrex reported earnings per share of $1.23 during the same quarter last year, which would indicate a negative year over year growth rate of 10.6%. The company is scheduled to issue its next quarterly earnings report on Friday, February 2nd.
On average, analysts expect that Cambrex will report full-year earnings of $3.09 per share for the current fiscal year, with EPS estimates ranging from $3.08 to $3.10. For the next fiscal year, analysts forecast that the firm will report earnings of $2.81 per share, with EPS estimates ranging from $2.67 to $2.95. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Cambrex.
Cambrex (NYSE:CBM) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.47 by $0.08. Cambrex had a return on equity of 23.42% and a net margin of 18.79%. The company had revenue of $112.60 million during the quarter, compared to analyst estimates of $108.44 million. During the same period in the prior year, the firm posted $0.47 earnings per share. The firm’s revenue was up 13.4% on a year-over-year basis.
Several equities analysts have recently issued reports on CBM shares. Craig Hallum reiterated a “buy” rating and set a $60.00 price target (down from $70.00) on shares of Cambrex in a research report on Tuesday, October 31st. Zacks Investment Research upgraded Cambrex from a “strong sell” rating to a “hold” rating in a report on Monday, January 15th. Finally, William Blair assumed coverage on Cambrex in a report on Tuesday, January 16th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. Cambrex has a consensus rating of “Hold” and a consensus price target of $60.50.
Cambrex (NYSE:CBM) traded up $0.27 on Friday, reaching $56.30. The company had a trading volume of 304,025 shares, compared to its average volume of 299,281. Cambrex has a 12-month low of $42.55 and a 12-month high of $62.95. The firm has a market cap of $1,840.00, a PE ratio of 18.46, a P/E/G ratio of 1.34 and a beta of 2.26.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. YorkBridge Wealth Partners LLC boosted its holdings in shares of Cambrex by 5.2% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 1,971 shares of the biotechnology company’s stock worth $118,000 after acquiring an additional 97 shares in the last quarter. Riverhead Capital Management LLC raised its position in shares of Cambrex by 90.3% in the second quarter. Riverhead Capital Management LLC now owns 2,664 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 1,264 shares during the period. Advisor Group Inc. raised its position in shares of Cambrex by 29.8% in the second quarter. Advisor Group Inc. now owns 2,681 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 615 shares during the period. Visionary Asset Management Inc. bought a new stake in shares of Cambrex in the third quarter valued at approximately $201,000. Finally, Trexquant Investment LP bought a new stake in shares of Cambrex in the third quarter valued at approximately $209,000.
WARNING: This piece of content was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/01/21/brokerages-expect-cambrex-co-cbm-will-post-earnings-of-1-10-per-share.html.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Get a free copy of the Zacks research report on Cambrex (CBM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.